July 26, 2016 2:55 PM ET


Company Overview of Meridian Life Science, Inc.

Company Overview

Meridian Life Science, Inc. manufactures and supplies antibodies, viral antigens, and critical assay reagents. The company’s product lines include animal sera, apoptosis and signal transduction, assay detection and other reagents, autoimmune reagents, bone and calcium metabolism, cancer research, cardiac markers, CD markers, collagen and extracellular matrix, cytokines and growth factors, cytoskeletal filaments and interstitial proteins, drug antibodies, enzymes, flow cytometry isotypic controls and blood lysing kit, hormones and steroids, immunoglobulin, animal, immunoglobulins, human, infectious diseases and toxins, lipoproteins, major histocompatibility antibodies, neuroscience reagents, ...

3471 River Hills Drive

Cincinnati, OH 45244

United States

Founded in 1983





Key Executives for Meridian Life Science, Inc.

Age: 55
Director of Marketing and Business Development
Vice President of Research and Development
Compensation as of Fiscal Year 2016.

Meridian Life Science, Inc. Key Developments

Meridian Life Science, Inc. Opens New Office in Beijing, China

Meridian Bioscience, Inc. announced that Meridian Life Science, Inc. has opened a new office in Beijing, China. The office is located on Chang-An Avenue (close to Tiananmen Square and government offices) on the 15th floor in the New China Life Insurance (NCI) Tower Center, in the heart of the central business district (CBD) of Beijing.

Meridian Life Science Receives SBIR II by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine

Meridian Life Science, Inc. announced that they have been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development will focus on optimization of growth and yield of the virus in cell culture, developing and characterizing a column-based purification process followed by formulation, inactivation and filling of the vaccine. This SBIR II, which follows an initial SBIR I awarded to MLS in 2013, will fund a 15 month research and development effort leading to scale up and manufacture of a rotavirus vaccine for use in clinical trials.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Meridian Life Science, Inc., please visit www.meridianlifescience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.